These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1253172)

  • 1. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice.
    Scheving LE; Haus E; Kühl JF; Pauly JE; Halberg F; Cardoso S
    Cancer Res; 1976 Mar; 36(3):1133-7. PubMed ID: 1253172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP; Peters WG; Willemze R
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
    Ho DH; Neil GL
    Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ; Karp JE; Vaughan WP
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.
    Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ
    Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
    Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR
    Exp Hematol; 1989 May; 17(4):364-7. PubMed ID: 2707318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin.
    Ritch PS; Occhipinti SJ; Cunningham RE; Shackney SE
    Cancer Res; 1981 Oct; 41(10):3881-4. PubMed ID: 7284997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.